There is healthy skepticism and there is this...

Going through applications for BTOG Trainee Representatives in oncology and respiratory medicine The most extraordinary group of dynamic, motivated, committed individuals So impressive So hard to decide Every single one would be excellent

On our next livestreams: a look at how #LungCancer affects young people and women, with moderator Dr. Isabel Preeshagul. Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2 Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together

Exciting news! @curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing @lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!

Happy to share our latest work, led by Dr Monaca. In a time-dependent analysis, we show that irAEs are associated with improved outcomes in ES-SCLC. Interestingly, neither high-grade irAEs nor the use of steroids appeared to negatively impact survival. www.sciencedirect.com/science/arti...

Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply. Extraordinary Think they need to review their PR skills (and conscience)

When the conference organizers ask if you can send in your slides a week in advance

❗️FLAURA2 approved by NICE❗️ Already on BlueTeq! Now an option for 1L EGFR+ pts Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen

❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️ The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍

This is an excellent series of discussions. Informed and informative. Highly recommend it. @katherinesleeman.bsky.social especially good, as she is always.

Very important dataset and a set forward to potential ambulatory delivery in the future.

🧐 Are you a 🇬🇧 Healthcare Professional treating lung cancer? 🤔 Do you want to learn how clinical research runs, whilst advancing your career? 💥 Be an Associate PI of a trial! 🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme Details here 👇 www.nihr.ac.uk/career-devel...

What!? Tiramisu is younger than my dad? Also the 1940s saw great additions to our cuisine. Weird how young ciabatta is! Fun chart shows several foods that were invented surprisingly recently. Source: buff.ly/nvQgUns

Wow Extraordinary times

New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer. Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM

Predicting surgical complexity following neo-adjuvant chemoIO Single centre 🇬🇧 study 👉 43% defined as complex 🔺 Risk score includes x3 variables: ❇️ CN2 ❇️ Absence of nodal response ❇️ PD-L1 >50% #ELCC25

LAURA OS update (LBA4) 👉 Now 31% maturity ❇️ 78% in PBO grp got Osi at PD ❇️ Improved PFS2 ❇️ Trend ⬆️ OS HR 0.67, not significant 💭 Confirm activity of Osi 💭 Crossover impacts OS difference 💭 Final maturity due @ 60% 💭 Surprised 1/3 Osi pts = no further treatment at PD #ELCC25

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25

Great ROS1 TKI summary slide from Julian Mazieres

COCOON: mitigating cutaneous toxicity of Amivantamab ✅ 60% reduction in Gr2+ dermatology AE ✅ Reduction scalp issues+ paronychia ✅ Fewer Ami dose amendments needed 💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy #ELCC25

Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC 👉 From TRUST I + II / PROFILE 1091 trials ✅ ORR 90% v 71% ✅ Improved PFS, HR 0.48 👉 Similar Gr3 TRAEs 💭 Ph3 head-2-head ongoing 💭 In meanwhile, this suggests Taletrectinib superior 💭 Would like to see CNS data #ELCC25

Tobemstomig (LAG3/PD1 bispecific) + chemo in 1L NSCLC 👉 Randomised Ph2 ❌ No ORR benefit ❌ No PFS benefit ❌ Higher Gr3+ TRAEs 💭 Not active combination 💭 Reality check on growing bispecific excitement 💭 Disappointing. LAG3 is hard to target. #ELCC25

Pan-KRASi: RMC-6236 👉 NSCLC pts from Ph1 study ❇️ 200mg = Ph3 dose ❗️TRAE: mucocutaneous, GI, liver ❗️ Rash prophylaxis needed 👉 Clinical data from G12X popn: ❇️ ORR 38% ❇️ mPFS = 9.8m Ph3 RASolve-301 underway 💭 Need breakdown by mutant type 💭 Press release: safe combo w Pembro #ELCC25

🇬🇧 healthcare has many challenges & shortcomings But we lead the world in lung cancer screening (many of these pioneers being on this paper) Now in routine clinical practice, causing stage shift. I see the effects every week. We need to bang the drum more about this 🥁

ORCHARD (module 10): Osi + Dato-Dxd post 1L Osi ❇️ ORR 36 - 43% ❇️ mPFS 9.5 - 11.7m ❇️ DoR longer in 6mg/kg grp ❗️ 65% Dato dose reduction ❗️ 60% Dato dose interr 💭 Active combination 💭 Toxic+ 💭 Not biomarker directed #ELCC25

BAY88 in HER2mut NSCLC Lower ORR, but similar DoR, if prior HER2 ADC (as opposed to treatment naive) #ELCC25

SAVANNAH: Osi+Savolitinib in MET amp/OE EGFR+ post 1L Osi 👉 Protocol evolved over time 👉 34% pts have MET OE/amp ❇️ ORR 56%; mDOR 9.9m ❇️ mPFS 7.5m ❗️32% Gr3+ AE: oedema, N&V, diarr ❗️Dose amendments mainly for Savo 💭 Good that includes MET OE 💭 Expected side effects, not insignificant

MARIPOSA final OS analysis ❇️ Significant HR 0.75 ❇️ 9% 3yr benefit ❇️ Projected mOS 4 years ❇️ Longer control of CNS disease ❗️At the cost of toxicity ❗️No data on duration of toxicity ❗️PROM and QoL data important More effective than Osimertinib Most suitable for higher risk pts #ELCC25

Love meetings in France: Madeleines & Petit four ❤️ Well done #ELCC25

Racing through France Eurostar the best way to travel from 🇬🇧 to #ELCC25 🏎️

Are you a respiratory or oncology trainee interested in lung cancer? Then apply to be part of the amazing @btog.bsky.social steering committee ⭐ Great experience ⭐ Great for your CV ⭐️ Great fun ⭐️ Great people ⭐ Great cause ❗️ Deadline 30.04.25

Here's the highlights reel from our 2025 Annual Conference #BTOG25 It's also available to watch on the home page of our website at www.btog.org

ICYMI: The US FDA grants zongertinib priority review for advanced HER2-positive NSCLC. 📰 Read the latest details in ILCN: bit.ly/3FvRaaR

BTOG is excited to call for Trainee Representatives from the Oncology and Respiratory specialities to apply to the BTOG Steering Committee. #LCSM Full details: www.btog.org/call-for-tra...

After Christine passed away in Oct 2024, her husband Sean met with her GP surgery to discuss her delayed EGFR+ #lungcancer diagnosis. Now, Banbury Cross Health Centre has made lung cancer in non-smokers part of their GP training. 💬 Patient advocacy changes conversations & outcomes. #LCSM

Congratulations to the winning posters from #BTOG25: Click to see the winners. www.btog.org/btog-2025-po...

HER2 mutated NSCLC increasingly important as a rest of new TKI show promising effectiveness in early phase trials Riyaz Shah and I discuss these, and other HER2 targeted treatments

New Podcast Alert! BTOG Does ... HER2. Featuring @tnewsomdavis.bsky.social, Dr Emma O'Dowd and Dr Riyaz Shah, listen wherever you get your podcasts (search 'BTOG') or online www.btog.org/btog-podcasts/ .

It's National Cancer CNS Day this Friday! 💙 🎥 The 2nd of our 3 special videos is out today! Watch the video about The Macmillan London CNS Development Pilot here: youtube.com/playlist?lis... Let’s make some noise for Cancer CNSs! 👏 #UKONS #NationalCancerCNSDay

📊 40% of #lungcancer patients say they didn’t get enough details about their diagnosis.* 📊 22% of UK EGFR+ patients don’t know their mutation type—even though it affects treatment.** Patients can’t make informed choices without the right info. #LCSM * LuCE 9th Report ** EGFR+ UK member survey

New chemotherapy unit & treatment centre at West Middlesex Hospital coming on nicely Chemo unit on top floor 😊 ETA 2026

Professor @drjnaidoo.bsky.social welcomed to the #BTOG25 stage as a Lung Cancer Legend & doesn’t disappoint. Lots of discussion on how we turn discussions on Small Cell Lung Cancer on its head. Lots of optimism in #SCLC coming from new standards & future treatments. #LCSM

Well #BTOG25 that’s a wrap for 2025 from #Belfast Thanks to @btog.bsky.social for 3 fantastic years in Belfast It’s been an absolute pleasure to have the BTOG community over with us for the last 3 years 🙏 Here’s to next year in Edinburgh! @drsanjaypopat.bsky.social @tnewsomdavis.bsky.social

The final session of #BTOG25 is ‘Non-medical Treatments in Cancer Patients’ chaired by Tom Newsom-Davis and Josie Roberts with   👉 Robert Thomas talking about vitamin D and sugar 👉 Chris Twelves talking about cannabinoids and cancer 👉 Robert Thomas talking about the evidence on gut health and cancer

That’s it! As our 23rd annual conference closes, we’d like to thank our speakers for sharing their valuable expertise, our hosts in Belfast and all of our amazing attendees. See you again next year for #BTOG26 in Edinburgh! March 3-5 #BTOG25 #LCSM

@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25

@stephenvliu.bsky.social on excitement in the Small Cell arena. PDL1/PD1 inhibition a practice changer, but so many potential game changers on the horizon from BITES To ADC, it’s exciting to see new drugs for an area of unmet need #BTOG25

Great session on systemic therapy for SCLC by @stephenvliu.bsky.social at #BTOG23 ➡️ BiTE engages, ADCs and many other agents showing promise ➡️ Possible role for radioligands ➡️ New never smokers phenotype emerging ➡️ Many reasons to be hopeful! @drjnaidoo.bsky.social @tnewsomdavis.bsky.social

Although @stephenvliu.bsky.social is hard to follow, we’ve just had an absolute tour de force by @drjnaidoo.bsky.social at #BTOG25 on #SCLC ➡️ Discusses NRG005 and the better outcomes for patients reviving twice daily radiotherapy. ➡️ Continued evidence of a benefit from PCI in LS-SCLC